Myasthenia gravis
RSS feedAntibodies to MuSK CRD are pathogenic in a mouse model of myasthenia gravis
Myasthenia gravis (MG) is caused by autoantibodies directed mainly against the acetylcholine receptor (AChR) or the MuSK receptor tyrosine kinase located at the neuromuscular junction. Several studies have reported immunoreactivity against the Frizzled cysteine-rich domain (CRD) of MuSK in patients, although the pathogenicity of the antibodies involved remains unknown. A collaboration involving several teams from … [Read more]
Towards European standardisation of registers and digital tools for myasthenia gravis
European experts met in conclave at the European Neuromuscular Center (ENMC) to define standards for the identification and management of patients with autoimmune myasthenia gravis. The ten patient registries currently in use or under development were analysed and compared, with expectations and objectives varying depending on the point of view (that of clinicians, patient associations, … [Read more]
The risk of false positivity of RACh autoantibodies persists
Italian biologists have looked retrospectively at the risk of obtaining âfalse positiveâ autoantibody results when investigating patients suspected of having myasthenia gravis, the study was limited solely to autoantibodies directed against the acetylcholine receptor (anti-RACh) of the 4,795 tests carried out over the last 20 years and revisited for the purpose, 50 true âfalse-positivesâ were … [Read more]
Tolerance of efgartimod in myasthenia gravis
Chinese researchers have studied the adverse reactions observed when efgartigimod, a new-generation immunosuppressant used, among other indications, in refractory autoimmune myasthenia, is administered: their work is based on pharmacovigilance data contained in the American database managed by the FDA (Food and Drug Administration), which is freely accessible and reports all types of adverse events linked … [Read more]
Towards a reassessment of certain contraindications to the use of drugs in autoimmune myasthenia gravis
American researchers have investigated the possible complications associated with the use of several classes of antibiotics known to be harmful to myasthenia gravis patients: data from patients followed between 2002 and 2022 in Cleveland (USA) and taking ciprofloxacin, levofloxacin (both fluoroquinolones) or azithromycin, were analysed retrospectively. The main endpoint was the occurrence of decompensation of … [Read more]
Researchers from the Institute at the 15th MGFA International Conference
Institute researchers at the 15th International MGFA ConferenceInstitute experts presented their work at the 15th International MGFA Conference on myasthenia gravis and associated disorders, held from 13 May to 15 May 2025 in The Hague, Netherlands. Organised by the Myasthenia Gravis Foundation of America (MGFA), this conference brings together neuromuscular researchers and healthcare professionals to … [Read more]
A new murine model of myasthenia gravis that is more effective and better suited to animal welfare
The Myasthenia gravis, etiology, pathophysiology & therapeutical approaches team, led by Rozen Le Panse at the Institute of Myology’s Myology Research Centre, has developed a new experimental murine model of myasthenia gravis (N-EAMG) that is at least as effective as the classic experimental model (C-EAMG) and offers several advantages. N-EAMG: is better suited to animal … [Read more]
Towards a European register of autoimmune myasthenia gravis cases
At a time when innovative therapies are being developed for refractory forms of autoimmune myasthenia gravis, the idea of setting up a European register is gaining ground: to this end, a group of experts comprising 11 neurologists, 4 neuropaediatricians and a physiotherapist was brought together to define the most relevant items for the future register, … [Read more]
Real-life pharmacovigilance identifies unreported side effects of eculizumab and alglucosidase alpha
Two Chinese teams looked at the real-life side-effects of eculizumab in the treatment of myasthenia and alglucosidase alfa in the treatment of Pompe disease. Analysis of data from the FDA’s pharmacovigilance system, FAERS (FDA Adverse Event Reporting System), revealed : 46,316 side-effect reports for eculizumab between 2007 and 2023, grouped under 461 preferred terms; 4,326 … [Read more]
Positive phase III results for nipocalimab in generalised myasthenia gravis
The Vivacity-MG3 phase III trial included 153 adults with generalised myasthenia to evaluate nipocalimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn). Of all the patients, 88% had anti-RACh autoantibodies, 11% had anti-MuSK autoantibodies and 2% had anti-LRP4 autoantibodies. Patients were randomised into two groups: 77 received nipocalimab and 76 a placebo, every fortnight … [Read more]
